In this paper, we examine the role of CD19 in the pathophysiology of DLBCL, review the evidence for CD19 as a target in DLBCL, and consider approaches to the use of anti‐CD19 therapy. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.